Difference between revisions of "Team:Queens Canada/Description"
(9 intermediate revisions by the same user not shown) | |||
Line 11: | Line 11: | ||
<div id="navbar"> | <div id="navbar"> | ||
− | + | <nav id="qgemnav"> | |
<ul> | <ul> | ||
<li><a href="https://2015.igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2015/f/fa/Qqq_IGEM_official_logo.png" /></a></li> | <li><a href="https://2015.igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2015/f/fa/Qqq_IGEM_official_logo.png" /></a></li> | ||
Line 24: | Line 24: | ||
</ul> | </ul> | ||
+ | |||
</li> | </li> | ||
<li><a href="https://2015.igem.org/Team:Queens_Canada/Notebook">Notebook</a></li> | <li><a href="https://2015.igem.org/Team:Queens_Canada/Notebook">Notebook</a></li> | ||
Line 31: | Line 32: | ||
<li><a href="https://2015.igem.org/Team:Queens_Canada/Background">Background</a></li> | <li><a href="https://2015.igem.org/Team:Queens_Canada/Background">Background</a></li> | ||
<li><a href="https://2015.igem.org/Team:Queens_Canada/Modeling">Modeling</a></li> | <li><a href="https://2015.igem.org/Team:Queens_Canada/Modeling">Modeling</a></li> | ||
− | <li><a href="https://2015.igem.org/Team:Queens_Canada/AFP_Scaffold"> | + | <li><a href="https://2015.igem.org/Team:Queens_Canada/AFP_Scaffold"> The Ice Queen</a></li> |
− | <li><a href="https://2015.igem.org/Team:Queens_Canada/Circ_AFP"> | + | <li><a href="https://2015.igem.org/Team:Queens_Canada/Circ_AFP"> Icefinity</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 49: | Line 50: | ||
<div id="motivation" style="padding: 60px 200px 20px 200px;"> | <div id="motivation" style="padding: 60px 200px 20px 200px;"> | ||
− | <h1> | + | <h1>PROJECT OVERVIEW</h1> |
+ | <p align="center"><em>Take a look at our <a href="#judgingcrit">Judging Criteria</a> below!</em></p> | ||
<h2>Motivation</h2> | <h2>Motivation</h2> | ||
Line 75: | Line 77: | ||
<h2>Icefinity</h2> | <h2>Icefinity</h2> | ||
<p>As an addition to our project this year, we decided to further explore the topic of AFPs and their variety of applications. Protein stability is of great importance when considering the use of AFPs in industry. Typical industrial processes often involve harsh conditions which will lead to denaturation (i.e. loss of function) for the protein. Therefore, in conjunction with improving the activity of the Type III AFP, we set out to increase the stability of the protein through circularization techniques.</p> | <p>As an addition to our project this year, we decided to further explore the topic of AFPs and their variety of applications. Protein stability is of great importance when considering the use of AFPs in industry. Typical industrial processes often involve harsh conditions which will lead to denaturation (i.e. loss of function) for the protein. Therefore, in conjunction with improving the activity of the Type III AFP, we set out to increase the stability of the protein through circularization techniques.</p> | ||
− | <p>Using Heidelberg’s intein biobrick <a href="http://parts.igem.org/Part:BBa_K1362000">BBa_K1362000</a>, we performed the intein-splicing reaction with the AFP to generate a circular protein: Icefinity. Heidelberg and other research parties have shown an increase in thermostability after cyclizing any protein.<sup>8, 9</sup> This summer, Circularization of the AFP has been a wonderful addition to our exploration of this fascinating protein. It also gave us the chance to make use of the open source iGEM registry and even improve upon Heidelberg’s construct. Read about our results <a href=" | + | <p>Using Heidelberg’s intein biobrick <a href="http://parts.igem.org/Part:BBa_K1362000">BBa_K1362000</a>, we performed the intein-splicing reaction with the AFP to generate a circular protein: Icefinity. Heidelberg and other research parties have shown an increase in thermostability after cyclizing any protein.<sup>8, 9</sup> This summer, Circularization of the AFP has been a wonderful addition to our exploration of this fascinating protein. It also gave us the chance to make use of the open source iGEM registry and even improve upon Heidelberg’s construct. Read about our results <a href="https://2015.igem.org/Team:Queens_Canada/Circ_AFP">here!</a> </p> |
− | <p>The QGEM team worked to develop Heidelberg’s intein biobrick by adding a T7 promoter to our submitted circular AFP construct. Inserting a promoter allows our biobrick to not only be a carrier, but also be an expression construct of our circular AFP. This biobrick part <a href="http://parts.igem.org/Part:BBa_K1831000">BBa_K1831000</a>is described in more detail on our <a href="https://2015.igem.org/Team:Queens_Canada/Parts">Parts Page</a> and the iGEM registry.</p> | + | <p>The QGEM team worked to develop Heidelberg’s intein biobrick by adding a T7 promoter to our submitted circular AFP construct. Inserting a promoter allows our biobrick to not only be a carrier, but also be an expression construct of our circular AFP. This biobrick part <a href="http://parts.igem.org/Part:BBa_K1831000">BBa_K1831000</a> is described in more detail on our <a href="https://2015.igem.org/Team:Queens_Canada/Parts">Parts Page</a> and the iGEM registry.</p> |
− | <h1> | + | <h1>REFERENCES</h1> |
<p>1. Canadian Transplant Society. (2014).</p> | <p>1. Canadian Transplant Society. (2014).</p> | ||
<p>2. "US Government Information on Organ and Tissue Donation and Transplantation". (2012). US Department of Health & Human Services.</p> | <p>2. "US Government Information on Organ and Tissue Donation and Transplantation". (2012). US Department of Health & Human Services.</p> | ||
Line 91: | Line 93: | ||
<div id="judgingcrit" style="padding: 60px 300px 20px 300px;"> | <div id="judgingcrit" style="padding: 60px 300px 20px 300px;"> | ||
− | <h1> | + | <h1>JUDGING CRITERIA</h1> |
<h2 style="color: #965A38;">Bronze</h2> | <h2 style="color: #965A38;">Bronze</h2> | ||
Line 107: | Line 109: | ||
<h2 style="color: #C98910;">Gold</h2> | <h2 style="color: #C98910;">Gold</h2> | ||
<ul> | <ul> | ||
− | <li>We have improved the characterization of the Calgary 2013 Team's BioBricks; <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189010">Bba_K1189010</a> and <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189011">Bba_K1189011</a>. | + | <li>We have improved the characterization of the Calgary 2013 Team's BioBricks; <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189010">Bba_K1189010</a> and <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189011">Bba_K1189011</a>. </li> |
+ | <li>We also used Heidelberg's intein BioBrick for our own purposes, improving upon its design by adding a T7 promoter to our BioBrick, allowing for direct expression of the protein without any subcloning.</a></li> | ||
<li>We also integrated the theme of education throughout our Human Practices Project; we organized a workshop for SHAD valley students, gave a public seminar on the applications our project, and participated in course development work. Take a look at our <a href="https://2015.igem.org/Team:Queens_Canada/Practices">Human Practices</a> page! </li> | <li>We also integrated the theme of education throughout our Human Practices Project; we organized a workshop for SHAD valley students, gave a public seminar on the applications our project, and participated in course development work. Take a look at our <a href="https://2015.igem.org/Team:Queens_Canada/Practices">Human Practices</a> page! </li> | ||
</ul> | </ul> |
Latest revision as of 13:42, 18 September 2015